Home / Health / Shingles Vaccine May Ward Off Dementia
Shingles Vaccine May Ward Off Dementia
28 Jun
Summary
- Shingles vaccine significantly lowers dementia risk in older adults.
- Studies show reduced dementia risk by 1.8% to 5.8% over years.
- Vaccination may protect brain health by reducing inflammation.
A growing body of evidence indicates that the shingles vaccine could substantially protect older adults against dementia. The varicella-zoster virus, which causes shingles, can trigger inflammation in the brain, disrupting brain health and potentially increasing dementia risk.
Recent studies reveal compelling findings: a U.S. nursing facility study showed a 5.8% lower dementia risk over four years for vaccinated individuals. International research from Wales, Australia, and Canada reported reduced dementia risks ranging from 1.8% to 3.5% over several years.
Scientists theorize the vaccine boosts overall immunity, helping to reduce neuroinflammatory processes. This protection may extend to the brain by preventing viral reactivation that could lead to amyloid and tau protein buildup, associated with Alzheimer's disease. The vaccine also guards against conditions like heart disease and stroke, which can impair brain function.
While Shingrix is the current FDA-approved vaccine in the U.S. for those 50 and older, earlier studies focused on Zostavax. Some research suggests the neuroprotective benefit might be stronger in women. Despite the benefits, vaccination rates remain low, with less than half of eligible U.S. adults having received the shot, highlighting a need for improved access and awareness.
